10 results about "Allergic condition" patented technology

The invention relates to a gene therapy vector nucleic acid construct for allergic diseases and a use method of the gene therapy vector nucleic acid construct. In particular to an expression cassette, the expression cassette comprises the following elements: a promoter, an optional first signal peptide coding sequence, a heavy chain coding sequence of an anti-IgE antibody, an optional linker sequence, an optional second signal peptide coding sequence and a light chain coding sequence of the anti-IgE antibody, and the invention also provides an adeno-associated virus vector containing the expression cassette. The gene expression framework of the adeno-associated virus vector can realize high-level expression of a target gene, and can be used for treating allergic diseases such as allergic asthma and chronic spontaneous urticaria.

Compositions and methods for treating diseases and conditions mediated by the high affinity IgE receptor (FcεRI) are provided. Also provided are antisense oligomers for modulating splicing of mRNA encoding a MS4A6A protein, optionally in addition to antisense oligomers for modulating splicing of mRNA encoding the FcεRIβ protein, thereby down-regulating cell-surface expression of FcεRI, and uses of the antisense oligomers for inhibiting mast cell degranulation, cytokine release, migration, and proliferation; for inhibiting anaphylaxis reactions in individuals, for treating allergic conditions in individuals, for reducing the incidence of allergic reactions in individuals, for treating individuals at risk of developing anaphylactic reactions, and for treating mast cell-related diseases in individuals.

The application belongs to the field of organic chemistry medicine, and particularly relates to a kind of thieno [3, 2-d] pyrimidine derivatives and preparation method and application thereof.The specific technical scheme is: a kind of thieno [3, 2-d] pyrimidine derivatives with specific structure is provided, and 43 new thieno [3, 2-d] pyrimidine derivatives are specifically provided.The thieno [3, 2-d] pyrimidine derivatives provided by the application have great pharmaceutical potential, can be used to prepare powerful, selective small molecule RIPK2 kinase activity inhibitors for specifically blocking RIPK2 dependent pro-inflammatory signaling, provide new optional, researchable drugs for treating bacterial infection, self-inflammatory disease, autoimmune disease, allergic condition and inhibiting tumor metastasis.

The invention provides an in-vehicle air purification control method and device, electronic equipment and a storage medium. The in-vehicle air purification control method comprises the steps that the concentration of allergens in a vehicle is detected every first preset duration; when it is detected that the allergen concentration is larger than the preset concentration, an air purifier of the vehicle is started, image data corresponding to each passenger in the vehicle is obtained every second preset duration, and a filter element fan of the air purifier operates at the first rotating speed; performing image recognition on the image data, and detecting whether a target passenger whose current behavior satisfies a preset allergic physiological behavior exists in the passengers according to an image recognition result; when it is detected that the target passenger exists, an air conditioner of the vehicle is turned on, and the air conditioner is switched to an internal circulation mode; the filter element fan is controlled to operate at a second rotating speed, and the second rotating speed is larger than the first rotating speed. According to the invention, active and accurate identification and response to the allergic condition of the passenger can be realized, so that the riding experience of the passenger is improved.

Contemplated compositions and methods employ betalains for treatment of various conditions, and especially osteoarthritis, sinusitis, contact dermatitis, acne, an allergic condition, reduced mental alertness, reduced physical strength, reduced physical endurance, and / or impaired mood.

The invention provides indolyl-pyridinones and related compounds, pharmaceutical compositions, their use for inhibiting signal transducer and activator of transcription 6 (STAT6), and their use in the treatment of a disease or condition, such as an inflammatory disorder, allergic condition, or proliferative disorder.

The present invention generally relates to compounds that are useful for inhibiting one or more trypsin-like S1 serine proteases, HGFA, matriptase, hepsin, KLK5 and / or TMPRSS2 as well as cysteine proteases including trypsin-like cysteine proteases (e.g. Cathepsin B). The present invention also relates to various methods of using the inhibitor compounds to treat or prevent viral infections, including those caused by coronaviruses and influenza, conditions associated with KLK5, various malignancies, pre-malignant conditions, and cancer.

Provided herein are methods and compositions for treating food allergies, infections, autoimmune conditions, and other allergic conditions. Also provided are methods for treating an infectious, autoimmune, or allergic disease in a subject comprising administering a composition comprising bacterium Anaerostipes caccae to the subject. Further aspects relate to a method for treating a food allergy or for reducing an allergic response to an allergen or for treating or preventing an anaphylactic response in a subject comprising administering a composition comprising bacterium Anaerostipes caccae and a prebiotic to the subject.

The invention provides compounds formula (I) and salts thereof: wherein R1-R2 have any of the values defined in the specification. The compounds are useful for treating conditions including Alzheimer's disease, Parkinson's disease, diabetes, cancer, inflammation, hyperresponsiveness, allergic conditions, asthma, and psychotic disorders such as schizophrenia. The compounds are also useful to lower IL-4, IL-5, or IL-15 levels in an animal.

The invention relates to a buffered aqueous composition comprising fluticasone propionate dissolved therein in a concentration of at least 20 µg / mL, wherein the composition further comprises a saponin component selected from the group consisting of escin, glycyrrhizin, and Quillaja saponaria extract, a buffer adjusted to a pH of from 4 to 8; and the surfactant poloxamer P407 in a con- centration of from 2.5 to 15 %w / v. The invention further relates to the use of the composition in the treatment of inflammatory and / or allergic conditions of the human body.